Project Grant R21AI185665

Award Date 5/23/24
Completion Date 3/31/26
Dollars Obligated $682K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing targeted antibiotic therapy strategies for Shigella infections among children in low-resource settings. The $746,813 award will support a multi-year study to characterize the impact of Shigella on diarrhea outcomes, evaluate the use of fecal biomarkers to identify Shigella cases, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $840,500 to the University of Chicago to investigate the role of alpha-defensins, antimicrobial peptides, in regulating the gut microbiome and host immune responses. The research aims to use advanced genetic and gnotobiotic (germ-free) approaches to define the specificity and homeostatic functions of alpha-defensins in...
This Project Grant awarded by the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to investigate how the gut microbiome composition impacts gastrointestinal (GI) and central nervous system (CNS) function in a mouse model of autism spectrum disorder (ASD). The $430,375 award to the partnership between Henry Ford Health and Michigan State University Health Sciences will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $195,213 to the University of California, Davis to investigate the mechanisms by which the gut microbiota, specifically short-chain fatty acids, inhibit the growth of the enteric pathogen Yersinia enterocolitica. The project aims to elucidate the molecular pathways underlying the sensitivity and resistance of...
This $950,664 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research to investigate the relationship between the gut microbiome and acute muscle loss in sepsis patients. The study aims to: 1) Determine the interaction between gut microbiota and body composition in predicting clinical outcomes among septic patients, and 2) Identify gut...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $126,096 to the University of California, San Diego (UCSD) for research focused on understanding the mechanisms of microbial competition between Salmonella typhimurium and the gut microbiome. The research aims to elucidate the metabolic interactions and host responses that influence Salmonella colonization, with the...
This $325,139 federal Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS), 93.350 program, aims to examine the feasibility of using target-specific polyclonal antibodies to neutralize bioactive molecules in the gut microbiome. The primary goals are to 1) determine the impact of six proteins identified as overabundant in inflammatory gut disorders, and 2) evaluate the ability of immunoglobulin Y (IgY) antibodies to neutralize the physiological impacts...
The National Institute of General Medical Sciences (NIGMS) awarded a $403,750 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Duke University to conduct research aimed at "Unraveling Effects of Gut and Blood Microbial Signatures on Immune Phenotypes and Organ Dysfunction in Sepsis." The research project, spanning May 1, 2025 to February 28, 2030, will utilize a meta-systems approach to integrate gut microbiome profiling, metabolomics, intestinal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $303,225 to The University of Iowa to research an engineered probiotic strain that could competitively exclude Salmonella bacteria from colonizing the intestinal epithelium of poultry. The overarching goal is to reduce Salmonella carriage in poultry, which would significantly improve food safety and decrease the...
The University of Maryland, Baltimore was awarded a $2,002,422 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to further understand the protective immunological mechanisms associated with vaccination and infection from major human-restricted enteric bacterial pathogens, such as Salmonella and Shigella, in both children and adults. The research will...

DEFINING HUMAN GUT MICROBIOME-MEDIATED PROTECTION AGAINST SHIGELLA INFECTION - PROJECT SUMMARY THE DIARRHEAL DISEASE SHIGELLOSIS IMPACTS 80-165 MILLION INDIVIDUALS AND CAUSES AN ESTIMATED 600,000 DEATHS WORLDWIDE EACH YEAR, PRIMARILY AMONG CHILDREN, AND NO EFFECTIVE VACCINES ARE AVAILABLE. THE HUMAN GUT MICROBIOME IS SUSPECTED TO PLAY A ROLE IN PROTECTION AGAINST SHIGELLA INFECTION, YET THIS IS LARGELY UNDEFINED. WE PROPOSE TO INVESTIGATE THE ROLE OF THE HUMAN GUT MICROBIOME IN PROTECTION AGAINST SHIGELLA BOTH IN A NOVEL MOUSE MODEL AND IN CULTURE. HUMAN CHALLENGE STUDIES WITH SHIGELLA HAVE IDENTIFIED INDIVIDUALS RESISTANT TO INFECTION, EVEN AMONG PEOPLE ASSUMED TO BE NAIVE TO THE PATHOGEN. WE WILL USE STOOL SAMPLES COLLECTED FROM HUMANS PRIOR TO SHIGELLA CHALLENGE TO CHARACTERIZE MICROBIOMES THAT ARE SENSITIVE AND RESISTANT TO SHIGELLA CHALLENGE. WE WILL PERFORM METAGENOMIC SEQUENCING TO IDENTIFY FEATURES OF INTEREST AND TRANSPLANT THESE COMMUNITIES INTO GERM-FREE MICE. WE WILL USE SHIGELLA SUSCEPTIBLE MICE DEFICIENT IN THE NAIP-NLRC4 INFLAMMASOME TO ESTABLISH A NOVEL HUMANIZED MOUSE MODEL FOR SHIGELLOSIS AND IDENTIFY FACTORS DRIVING MICROBIOME-MEDIATED PROTECTION. OUR PRELIMINARY DATA SUGGESTS THAT SPECIFIC HUMAN BACTERIAL STRAINS CAN DECREASE S. FLEXNERI COLONIZATION, BUT ARE NOT AS EFFECTIVE AS COMPLEX HUMAN MICROBIOMES, WHICH CAN PROVIDE FULL PROTECTION. WE WILL FURTHER CHARACTERIZE BACTERIAL MECHANISMS INHIBITING SHIGELLA GROWTH AND VIRULENCE IN CULTURE USING DIVERSE GUT BACTERIAL CULTURE COLLECTIONS AND MULTIPLE EXPERIMENTAL APPROACHES. NEW THERAPEUTIC STRATEGIES ARE ESSENTIAL FOR FUTURE PREVENTION AND TREATMENT OF SHIGELLA GIVEN THE EXPANSION OF ANTIBIOTIC RESISTANT STRAINS. THIS PROPOSAL WILL IDENTIFY KEY BACTERIAL SPECIES IMPORTANT FOR SHIGELLA RESISTANCE THAT CAN PAVE THE WAY FOR MICROBIAL THERAPEUTICS AND PROPHYLACTIC REGIMENS IN HIGH-RISK INDIVIDUALS, INCLUDING CHILDREN. IT WILL ALSO ESTABLISH FOR THE FIRST TIME A SHIGELLA SUSCEPTIBLE MOUSE MODEL WITH A HUMAN MICROBIOME, ENABLING NEW AVENUES OF RESEARCH INTO GUT MICROBIOME-SHIGELLA INTERACTIONS.

Posted 5/23/24, 12:00 AM